General
NEJM Series on Clinical Trials
NEJM Webpage
Introduction: Woodcock. Clinical Trials Series. N Engl J Med 2016; 374:2167
- Fiore. Integrating Randomized Comparative Effectiveness Research with Patient Care. N Engl J Med 2016; 374:2152-2158
- Bhatt. Adaptive Designs for Clinical Trials. N Engl J Med 2016; 375:65-74
- Ford. Pragmatic Trials. N Engl J Med 2016; 375:454-463
- Pocock. The Primary Outcome Fails — What Next?. N Engl J Med 2016; 375:861-870
- Pocock. The Primary Outcome Is Positive — Is That Good Enough? N Engl J Med 2016; 375:971-979
- DeMets. Data Monitoring Committees — Expect the Unexpected. N Engl J Med 2016; 375:1365-1371
- Pfeffer. Lessons in Uncertainty and Humility — Clinical Trials Involving Hypertension. N Engl J Med 2016; 375:1756-1766
- Yusuf. Interpreting Geographic Variations in Results of Randomized, Controlled Trials. N Engl J Med 2016; 375:2263-2271
- Rosenblatt. The Large Pharmaceutical Company Perspective. N Engl J Med 2017; 376:52-60
- Moscicki. Drug-Development Challenges for Small Biopharmaceutical Companies. N Engl J Med 2017; 376:469-474
- Grady. Informed Consent. N Engl J Med 2017; 376:856-867
- Faris. An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials. N Engl J Med 2017; 376:1350-1357
- Ramsey. Academic, Foundation, and Industry Collaboration in Finding New Therapies. N Engl J Med 2017;376:1762-1769
- Newhouse. Health Policy Trials. N Engl J Med 2017; 376:2160-2167
- Woodcock. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med 2017;377:62-70
- Frieden. Evidence for Health Decision Making — Beyond Randomized, Controlled Trials. N Engl J Med 2017; 377:465-475
- Choudhry. Randomized, Controlled Trials in Health Insurance Systems. N Engl J Med 2017;377:957-964
- Mauri. Challenges in the Design and Interpretation of Noninferiority Trials. N Engl J Med 2017;377:1357-1367